Novavax Shifts From COVID Sales to R&D Focus While Updating 2025 Forecast
Novavax, Inc. (NASDAQ:NVAX) ranks among the most oversold biotech stocks to invest in. Novavax, Inc.
Novavax Inc (NVAX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Shah Capital Management Himanshu H. Shah | 11,811,780 | $102,408,133 | +3% | 18.32% |
| 2. | D E Shaw D. E. Shaw | 4,274,079 | $37,056,265 | +9% | 0.02% |
| 3. | Coatue Management Philippe Laffont | 3,836,986 | $33,266,669 | 0.08% | |
| 4. | 20,252,000 | $23,236,233 | +162% | 0.03% | |
| 5. | 2,549,900 | $22,107,633 | +5% | 0.35% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.50 | 1,000 | $6,500.00 | 14,473 | 2023-03-10 | Filing | |
| $7.04 | 2,000 | $14,088.00 | 13,473 | 2023-03-07 | Filing | |
| $7.48 | 3,000 | $22,453.50 | 11,473 | 2023-03-06 | Filing | |
| $139.64 | 700 | $97,748.00 | 2,800 | 2021-05-19 | Filing | |
| $48.83 | 1,500 | $73,245.00 | 1,500 | 2020-06-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.02 | 4,150 | $37,435.08 | 14,770 | 2024-12-13 | Filing | |
| $8.00 | 5,400 | $43,200.00 | 51,760 | 2024-12-31 | Filing | |
| $8.48 | 4,600 | $39,008.00 | 57,160 | 2024-12-24 | Filing | |
| $14.09 | 7,500 | $105,675.00 | 61,760 | 2024-06-21 | Filing | |
| $14.28 | 1,107 | $15,807.96 | 69,260 | 2024-06-18 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 15,194,563 | $131,736,862 | 0% | |
| 2. | 12,773,053 | $110,742,371 | 0% | |
| 3. | 7,196,719 | $62,395,554 | 0% | |
| 4. | 6,880,481 | $59,653,770 | 22.91% | |
| 5. | 3,792,064 | $32,882,382 | 0% |
News See All
9 Oversold Biotech Stocks to Invest In
Biotech companies are making a solid comeback following an extended slump as investors shift their focus back to value and healthcare.
Novavax, Inc. (NASDAQ:NVAX) Q3 2025 Earnings Call Transcript
Operator: Good morning, and welcome to Novavax's Third Quarter 2025 Financial Results and Operational Highlights Conference Call.
Novavax (NVAX) Gains Momentum with Sanofi Deal and Analyst Endorsement
Novavax, Inc. (NASDAQ:NVAX) is one of the top long-term biotechnology stocks to buy. On October 24, Cantor Fitzgerald initiated coverage of Novavax, Inc.
Top 8 Long-Term Biotechnology Stocks to Buy
Momentum in biotechnology stocks is accelerating after years of underperformance.
11 Cheap Biotech Stocks to Buy According to Hedge Funds
Mizuho's Jared Holz appeared on CNBC's "Closing Bell Overtime" on July 8 to talk about whether the biotech industry is prepared for a breakthrough.
10 Best Biotech Stocks to Buy Under $10
The head biotech analyst at Goldman Sachs, Salveen Richter, appeared on CNBC's "Squawk Box" on July 25 to discuss various topics, including the current status of the biotech industry and what to expect...
Novavax Strengthens Position with Vaccine Approval and Sanofi Partnership
Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company focused on recombinant protein-based vaccines using nanoparticle and Matrix-M adjuvant technology.